NAVI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Navient Corp (NAVI) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is deteriorating, analysts have significantly lowered price targets with mostly negative ratings, and there are no strong positive catalysts or trading signals to justify a buy. The technical indicators and options data also do not support a bullish outlook.
The MACD is positive and expanding, suggesting slight bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. The stock is trading near its pivot point of 8.142, with resistance at 8.348 and support at 7.935. Overall, the technical indicators do not strongly support a buy.
NULL identified. There are no significant insider or hedge fund trading trends, and no recent congress trading data. The MACD suggests slight bullish momentum, but it is not strong enough to outweigh other negative factors.
Analysts have significantly lowered price targets and ratings, citing weak Q4 performance, credit deterioration, and underwhelming 2026 guidance.
Financial performance is poor, with revenue, net income, EPS, and gross margin all showing significant YoY declines in Q4
The SAVE plan ending could increase debt burdens for borrowers, indirectly affecting Navient's business.
Options data shows low call volume and a high put-call ratio, indicating bearish sentiment.
In Q4 2025, Navient's revenue dropped by 21.36% YoY to $762 million. Net income fell to -$5 million, a 120.83% YoY decline. EPS dropped to -0.05, down 122.73% YoY, and gross margin decreased to 17.59%, a 29.86% YoY decline. These metrics indicate significant financial deterioration.
Analysts have lowered price targets significantly, with most ratings being Hold, Sell, or Underperform. The consensus reflects concerns about weak guidance, credit deterioration, and poor financial performance. There is no indication of a positive turnaround in the near term.
